No Data
No Data
Express News | [Change Report] SBI Securities reports a reduction in the Shareholding ratio of Medical Net (3645.JP) to 4.19%.
Emerging markets stock digest: AR Advanced has significantly continued to rise, and the data sector has rebounded.
Continuous rise. After the close of trade on the 15th, the monthly revenue for October 2024 will be announced, viewed as favorable news.
Hot stocks digest (morning session): Milbon, Joyy Inc. American Depositary Shares, Aozora etc
Marked increase. It seems that a management policy briefing by the next president was held over the weekend.
Medical N continues to rise, partnering with ZAICO to start offering 'zaico for dental' for dental clinics.
Rising further. Stem Inc. announced the start of providing 'zaico for dental' to dental clinics by partnering with ZAICO after the close of trading on the 15th, which has been well received. Offering 'zaico for dental,' a cloud inventory management system provided by ZAICO specialized for the dental industry, leveraging the Medical Net Group's network of dental healthcare professionals. In addition, collaborating with dental dealers to provide not only inventory management services for dental clinics, but also to develop...
Japanese stock buybacks this week (10/28~11/1)
――――10/28――――$Macnica Holdings(3132.JP)$ will buy back up to 2 million shares, 1.11% of its outstanding shares (excluding its own shares), for an amount of JPY¥ 3 billion.$Mitsubishi Logistics(9301.
Emerging markets stocks digest: Fulta continues to rise significantly, sea U sea hits the daily limit.
<4598> DELTA-P 533 +47 surged significantly. After the trading on the 28th, the progress of the phase 1/2 clinical trial of DFP-10917 and VEN was announced, which is considered a positive development. DFP-10917, when given as a low-dose continuous infusion, is believed to be highly safe, stops cancer cells in the G2/M phase, and induces apoptosis (programmed cell death). Therefore, a strong synergistic effect can be expected when combined with VEN (a BCL-2 inhibitor). Currently, a phase 1 clinical trial is underway.